Drilldown: Medicines

Codeine (2)

Other values:

Search

None (13)

Other values:

Search

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Irreversible non-selective MAO inhibitor (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

Search

None (50) · ADHD, narcolepsy (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (52) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 25 mg (1) · 5 mg PO (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (52) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (52) · 200 mg/d (1) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · 360 mg/day (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (49) · Oral (5) · Oral (prescribed) (1) · PO (only formulation marketed in the US). (1) · transdermal (1)

None (50) · 20–60 min (oral) (1) · 30–60 min (1) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (50) · 4–6 hours (1) · Chronic daily dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1) · Long (1)

None (50) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2.5–3 hours (1) · 2–3 h (parent compound) (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (50) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~75–90% (oral) (1)

None (49) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (3) · Category C (per Desoxyn label) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (49) · Rx-only (1) · Rx-only in US (1) · Schedule II (4) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)